Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Biotech Growth Trust approves buyback of up to 14.99% of shares
Shareholders of Biotech Growth Trust voted in favour of a special resolution to buy back up to 14.99% of the issued share capital, with 99.7% approval. At the time of the annual general meeting, 21,956,234 ordinary shares were issued. The measure is part of the capital management strategy, details of which were set out on 15 October 2025; the formal voting result and the text of the resolution will be published and filed at Companies House. » More on de.investing.com
Biotech Growth Trust applies to extend share buyback programme
Biotech Growth Trust will renew the authority to repurchase its own shares and asks shareholders to approve this at the annual general meeting on 12 November 2025. To date the investment trust has repurchased 2,710,338 shares (10.7% of the capital) and expects the current capacity to be exhausted within weeks or months. The board is proposing authority to buy up to 14.99% of the issued shares, valid until the annual general meeting in 2026. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsIn 1999, BIOTECH GROWTH TR. LS-,25 has already paid €0.015 in dividends. The last payout was in August 1999.
Financials
In the last quarter, BIOTECH GROWTH TR. LS-,25 had revenue of €49.67m and net profit of €46.14m
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 49.67m | - |
| Gross profit | 47.91m | - |
| Net profit | 46.14m | - |
| EBITDA | 46.83m | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €301.52m |
Number of shares | 18.76m |
52-week high/low | €21.29 - €13.69 |
| Dividends | No |
Beta | 0.61 |
P/E ratio | 2.75 |
PEG ratio | 0.00 |
P/B ratio | 0.85 |
P/S ratio | 2.38 |
Company profile
The Biotech Growth Trust PLC is a closed ended equity mutual fund launched by Frostrow Capital LLP. It is co-managed by OrbiMed Capital LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the biotechnology sector. The fund invests in stocks of companies across all market capitalizations. It employs fundamental analysis to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotechnology Index. It was previously known as Finsbury Emerging Biotechnology Trust PLC. The Biotech Growth Trust PLC was formed on May 20, 1997 and is domiciled in the United Kingdom.
| Name | BIOTECH GROWTH TR. LS-,25 |
| CEO | Samuel David Isaly |
| Headquarters | London,
United Kingdom |
| Website | |
| IPO | 23/06/1997 |
Ticker symbols
| Exchange | Symbol |
|---|---|
London Stock Exchange | BIOG.L |
London | BIOG.L |